ArticleExperimental and therapeutic medicine2013
Anticoagulation therapy in patients with chronic obstructive pulmonary disease in the acute exacerbation stage.
Article in Experimental and therapeutic medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.
- Effects of oral anticoagulant therapy in patients with pulmonary diseases.Frontiers in cardiovascular medicine · 2022Pooled it
- Benefits and risks of low molecular weight heparin in patients with acute exacerbation of chronic obstructive pulmonary disease: a meta-analysis of randomized controlled trials.Inflammopharmacology · 2020Pooled it
- Study on the Relationship between AAD and Clinical Features in Emergency Ward Patients and the Application Effect of Probiotics.Contrast media & molecular imaging · 2022Trial
- Nebulized heparin and salbutamol versus salbutamol alone in acute exacerbations of chronic obstructive pulmonary disease requiring mechanical ventilation: a double-blind randomized controlled trial.Korean journal of anesthesiology · 2020Trial
- Differences in systemic inflammation and prethrombotic biomarkers between AECOPD patients with and without pulmonary hypertension.Journal of inflammation (London, England) · 2026Article
- Bioinformatic Insights and XGBoost Identify Shared Genetics in Chronic Obstructive Pulmonary Disease and Type 2 Diabetes.The clinical respiratory journal · 2025Article
- Nomogram model of mortality risk in patients with chronic obstructive pulmonary disease in intensive care unit: based on MIMIC-IV database and external validation study.Frontiers in medicine · 2025Article
- Heparin beyond anti-coagulation.Current research in translational medicine · 2021Review
- Effect of urban air pollution on CRP and coagulation: a study on inpatients with acute exacerbation of chronic obstructive pulmonary disease.BMC pulmonary medicine · 2021Article
- Optimal Choice of Pharmacological Therapy - Prevention of Stroke and Assessment of Bleeding Risk in Patients with Atrial Fibrillation.International journal of preventive medicine · 2019Article
- Heparin: 100 years of pleiotropic effects.Journal of thrombosis and thrombolysis · 2016Review
- COPD and Anticoagulation Therapy: Time for a New Approach?International journal of chronic obstructive pulmonary diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This aim of this study was to investigate the effects of intervention with low-molecular-weight heparin calcium on the pulmonary function and blood coagulation function of patients with chronic obstructive pulmonary disease (COPD) in the acute exacerbation stage. A total of 70 patients with COPD in the acute exacerbation stage were selected and randomly divided into the control group (32 cases) and the anticoagulation group (38 cases). The patients of the control group were treated with oxygen therapy, spasmolysis, asthmarelief, cough relief and sputum reduction. The patients in the anticoagulation group, in addition to the conventional therapy used the control group, were also treated with low-molecular-weight heparin calcium 4100 AXaIU/time. by abdominal subcutaneous injection once every 12 h. For both groups, one treatment course lasted 10 days. The pulmonary function indicators and blood coagulation indicators of the two groups before and after treatment were determined. Following treatment, the pulmonary function and arterial blood gas indicators of the two groups were significantly better than those before treatment, and the extents of the improvements in the anticoagulation group were significantly greater than those in the control group. The D-dimer level and blood coagulation indicators [international normalized ratio (INR), prothrombin time (PT), activated partial thromboplastin time (APTT) and fibrinogen (FIB) concentration] of the anticoagulation group were significantly improved compared with those prior to treatment, but there were no significant differences between these measures before and after treatment for patients in the control group. No serious adverse reaction occurred in the anticoagulation group. Although, the conventional therapy was able to improve the overall condition of patients with COPD, it was not able to effectively improve the hypercoagulative state of the patients' blood. The combination of conventional therapy with low-molecular-weight heparin calcium anticoagulation improved the blood coagulation and pulmonary functions of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.